Skip to Content

Micafungin Dosage

Applies to the following strength(s): 100 mg ; 50 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Esophageal Candidiasis

150 mg via IV infusion once a day
Duration of therapy: Has ranged from 10 to 30 days (mean duration: 15 days)

Usual Adult Dose for Fungal Infection Prophylaxis

50 mg via IV infusion once a day
Duration of therapy: Has ranged from 6 to 51 days (mean duration: 19 days)

Comments:
-Efficacy against infections due to fungi other than Candida has not been established.

Approved indication: Prophylaxis of Candida infections in hematopoietic stem cell transplant recipients

Usual Adult Dose for Candidemia

100 mg via IV infusion once a day
Duration of therapy: Has ranged from 10 to 47 days (mean duration: 15 days)

Comments:
-Not adequately studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida infections.

Approved indications: Treatment of patients with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses

Usual Pediatric Dose for Esophageal Candidiasis

4 months or older:
30 kg or less: 3 mg/kg via IV infusion once a day
Greater than 30 kg: 2.5 mg/kg via IV infusion once a day
Maximum dose: 150 mg per day

Usual Pediatric Dose for Fungal Infection Prophylaxis

4 months or older: 1 mg/kg via IV infusion once a day
Maximum dose: 50 mg per day

Comments:
-Efficacy against infections due to fungi other than Candida has not been established.

Approved indication: Prophylaxis of Candida infections in hematopoietic stem cell transplant recipients

Usual Pediatric Dose for Candidemia

4 months or older: 2 mg/kg via IV infusion once a day
Maximum dose: 100 mg per day

Comments:
-Not adequately studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida infections.

Approved indications: Treatment of patients with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Dose Adjustments

Concomitant use of mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, voriconazole, itraconazole, amphotericin B, ritonavir, or rifampin: No adjustment recommended.

Precautions

Consult WARNINGS section for dosing related precautions.

Safety and efficacy have not been established in patients younger than 4 months.

Dialysis

Micafungin is not dialyzable. Supplementary dosing is not required following hemodialysis.

Other Comments

Administration advice:
-Administer by IV infusion only.
-Infuse micafungin over 1 hour; more rapid infusions may result in more frequent histamine mediated reactions.
-Flush existing IV line with 0.9% Sodium Chloride Injection, USP before micafungin infusion.
-Administer solutions with concentrations above 1.5 mg/mL via central catheter in pediatric patients (to minimize risk of infusion reactions).

Storage requirements:
-Unopened vials: Should be stored at room temperature (25C [77F]); excursions permitted to 15C to 30C (59F to 86F).
-Reconstituted product: May be stored in original vial for up to 24 hours at room temperature (25C [77F]).
-Diluted infusion: Should be protected from light; may be stored for up to 24 hours at room temperature (25C [77F]).

Reconstitution/preparation techniques: The manufacturer's product information should be consulted.

IV compatibility:
-Compatible IV solutions: 0.9% Sodium Chloride Injection, USP (without bacteriostatic agent); 5% Dextrose Injection, USP
-Other medications should not be mixed or co-infused with micafungin; micafungin precipitates when mixed directly with many other commonly used medications.

Monitoring:
-Hematologic: Worsening hemolysis or hemolytic anemia in patients who develop clinical/laboratory evidence of such conditions (during therapy)
-Hepatic: Worsening hepatic function in patients who develop abnormal liver function tests (during therapy)
-Renal: Worsening renal function in patients who develop abnormal renal function tests (during therapy)

Hide